Less than two months after being acquired by BGI-Shenzhen, Complete Genomics has started joint technology development with its new parent, is supporting BGI-led research projects, and has begun to integrate its sales force with BGI as it continues to serve existing customers of its human whole-genome sequencing service.

Longer term, the Mountain-View, Calif.-based company – now a wholly-owned subsidiary of BGI – plans to collaborate closely with BGI Health, BGI's clinical arm, to provide sequencing services to the clinical market.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.